Clinical Trial Update: CANVAS - CANagliflozin cardioVascular Assessment Study [Phase 3]

View source ↗

Summary

Phase 3 CANVAS trial assessing canagliflozin for cardiovascular outcomes in type 2 diabetes; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases
• Type 2 Diabetes Mellitus

Drugs mentioned

• Canagliflozin (canagliflozin)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Diabetes Mellitus, Type 2, Cardiovascular Diseases | Phase 3 | Status: COMPLETED | Results posted: 2018-12-07